期刊
JOURNAL OF MAGNETIC RESONANCE IMAGING
卷 34, 期 4, 页码 764-773出版社
WILEY-BLACKWELL
DOI: 10.1002/jmri.22662
关键词
resting-state functional MRI; hippocampus; Alzheimer's disease; donepezil
资金
- Eisai Inc.
- Pfizer Inc.
- NIH-NIA [AD 20279]
- NIH [2R01AG020279-06A2, 2R01DA010214-11A1, R01 AG20279]
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- Extendicare Foundation
- Advancing Healthier Wisconsin Endowment for Research
- NHLBI, NIH Women's Health Initiative [N01-WH 44221]
- China Scholarship Council [CSC20070320]
- Bristol Myers Squibb
- Danone
- Elan
- Genentech
- Octapharma AG
- General Clinical Research Center [M01 RR00058]
- DANA Foundation
Purpose: To identify the neural correlates of cognitive improvement in mild Alzheimer's disease (AD) subjects following 12 weeks of donepezil treatment. Materials and Methods: Resting-state functional connectivity magnetic resonance imaging (R-fMRI) was used to measure the hippocampal functional connectivity (HFC) in 14 mild AD and 18 age-matched normal (CN) subjects. AD subjects were scanned at baseline and after donepezil treatment. CN subjects were scanned only at baseline as a reference to identify regions correlated or anticorrelated to the hippocampus. Before each scan, participants underwent cognitive, behavioral, and functional assessments. Results: After donepezil treatment, neural correlates of cognitive improvement measured by Mini-Mental State Examination scores were identified in the left parahippocampus, dorsolateral prefrontal cortex (DLPFC), and inferior frontal gyrus. Improvement in AD Assessment Scale-cognitive subscale scores correlated with the HFC changes in the left DLPFC and middle frontal gyrus. Stronger recovery in the network connectivity was associated with cognitive improvement. Conclusion: R-fMRI may provide novel insights into the brain's responses to AD treatment in clinical pharmacological trials, and also may predict clinical response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据